Integrating Therapeutic Advances to Improve Current Practices in Myeloma Patient Care

Atlanta, Georgia
Friday, December 08, 2017
Integrating Therapeutic Advances to Improve Current Practices in Myeloma Patient Care
Friday, December 08, 2017 8:00 AM - 11:00 AM (Eastern Time)

Georgia World Congress Center
Murphy Ballroom 1-2
285 Andrew Young International Blvd NW
Atlanta, Georgia 30313
United States

Map and Directions

Join us on Friday, December 8, 2017 for a CME-certified Friday Satellite Symposium preceding the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.


7:00 AM – 8:00 AM
Registration and Breakfast

8:00 AM – 11:00 AM
Scientific Program

Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with multiple myeloma.

Program Overview
Improving outcomes for patients with multiple myeloma (MM) requires building on the foundation of current therapies with new agents and combinations, recognizing the nature of each individual patient’s disease, and providing a personalized approach to treatment. To help hematologist-oncologists optimize the care they provide to patients with MM, our expert faculty will provide updated information on selecting the most appropriate therapy based on patient profile, clinical evidence, and assessment of risk-versus-benefit. 

Through the use of iPad-based technology developed to enhance interactivity and learner engagement, this symposium will present a series of evidence-based presentations and interactive patient-based video vignettes. Real-world case studies will provide an opportunity for learners to respond to practice-related issues, covering such factors as patient profile, clinical evidence, and assessment of risk/benefit to achieve the best possible durable response.

Learning Objectives
At the conclusion of this activity, participants should be better able to:
  • Evaluate current clinical evidence on precision medicine
  • Define patient prognosis and risk stratification utilizing R-ISS, FISH, and imaging
  • Select treatment combinations in the frontline setting based on risk and patient-specific characteristics
  • Assess treatment response to induction therapy and determine which patients will benefit from consolidation and/or maintenance therapy
  • Select an appropriate course of therapy for patients who have relapsed from, or become refractory to initial treatment
Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Access Statement
RedMedEd complies fully with the legal requirements of the Americans With Disabilities Act. If you are in need of special accommodation, please indicate your need in writing or contact Karen Tenaglia at 610.251.6841 or ktenaglia@redmeded.com.

Jointly provided by


Support for this activity has been provided through educational grants from Amgen and Celgene Corporation.
 

Contact Information

  • Karen Tenaglia, RedMedEd
    Phone: 610.251.6841
© 2018
Quick, easy and affordable online event registration and event management software for all event sizes.